Biopharmaceutical firm Quell Therapeutics has leased 11,000 sq ft at Imperial College ThinkSpace’s White City campus.
The business has designed and built its own laboratory and office space within the 187,000 sq ft Translation & Innovation Hub at the west London campus.
Quell is aiming to develop therapies for the management and treatment of a range of conditions including solid organ transplant rejection, autoimmune illnesses and inflammatory diseases.
Iain McGill, chief executive officer of Quell Therapeutics, said: “The existing shell-and-core floor at the I-HUB had all the necessary infrastructure to allow us to build the labs and offices to our specific requirements.”
JLL advised Imperial College ThinkSpace and Savills advised Quell on the deal.
To send feedback, e-mail louise.dransfield@egi.co.uk or tweet @DransfieldL or @estatesgazette
